Peter C. Farrell Sells 2,000 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total transaction of $497,480.00. Following the completion of the sale, the director now owns 83,204 shares in the company, valued at $20,696,162.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

ResMed Stock Up 2.1 %

Shares of RMD traded up $5.32 during trading hours on Friday, reaching $253.86. The company's stock had a trading volume of 336,805 shares, compared to its average volume of 1,048,182. The company has a 50 day moving average of $243.12 and a two-hundred day moving average of $221.39. ResMed Inc. has a 1-year low of $140.81 and a 1-year high of $260.49. The firm has a market cap of $37.27 billion, a price-to-earnings ratio of 33.52, a P/E/G ratio of 1.80 and a beta of 0.69. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. ResMed's revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.64 EPS. As a group, research analysts predict that ResMed Inc. will post 9.22 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a $0.53 dividend. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a yield of 0.84%. ResMed's dividend payout ratio is currently 28.08%.

Analyst Ratings Changes

RMD has been the subject of several recent analyst reports. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Wolfe Research restated an "underperform" rating and issued a $180.00 target price on shares of ResMed in a research report on Wednesday, September 18th. KeyCorp lifted their price target on ResMed from $251.00 to $266.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Needham & Company LLC restated a "hold" rating on shares of ResMed in a report on Friday, October 25th. Finally, Bank of America boosted their price target on shares of ResMed from $240.00 to $270.00 and gave the stock a "buy" rating in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $225.70.

Hedge Funds Weigh In On ResMed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RMD. OFI Invest Asset Management bought a new position in shares of ResMed during the 2nd quarter valued at $32,000. Ashton Thomas Securities LLC bought a new position in ResMed during the third quarter valued at about $34,000. Versant Capital Management Inc lifted its position in shares of ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock worth $35,000 after buying an additional 120 shares during the last quarter. Financial Connections Group Inc. bought a new stake in shares of ResMed during the 2nd quarter worth about $37,000. Finally, Blue Trust Inc. raised its stake in shares of ResMed by 182.7% in the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 137 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.